PepGen (PEPG) Share-based Compensation (2021 - 2026)
PepGen (PEPG) reported Share-based Compensation of $2.9 million for Q1 2026, down 16.81% on a YoY basis from $3.4 million in Q1 2025, and up 17.15% sequentially from $2.4 million in Q4 2025.
PepGen (PEPG) Share-based Compensation (2021 - 2026) Analysis & Trends
PepGen (PEPG) has 6 years of Share-based Compensation data on file, last reported at $2.9 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 16.81% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $11.1 million (down 13.73% YoY), and the FY2025 full-year result was $15.8 million, down 46.8% from the prior year.
- Share-based Compensation improved to $2.9 million in Q1 2026, from $2.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $25.6 million in Q2 2025 to a low of $815000.0 in Q1 2022.
- A 5-year average of $4.8 million and a median of $2.4 million in 2025 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation jumped 3359.64% in 2022 and slumped 91.7% in 2023, its largest moves.
- Tracing PEPG's Share-based Compensation over 5 years: stood at $23.1 million in 2022, then tumbled by 91.7% to $1.9 million in 2023, then soared by 74.14% to $3.3 million in 2024, then slipped by 27.19% to $2.4 million in 2025, then climbed by 17.15% to $2.9 million in 2026.
- Business Quant data shows PEPG's Share-based Compensation at $2.9 million in Q1 2026, $2.4 million in Q4 2025, and $2.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | PepGen | 145.09 Mn | 145.09 Mn | - | 2.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.86 Mn |
| Mar 31, 2026 | 2.86 Mn |
| Dec 31, 2025 | 2.44 Mn |
| Dec 31, 2025 | 2.44 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Jun 30, 2025 | 25.60 Mn |
| Jun 30, 2025 | 25.60 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 1.92 Mn |
| Dec 31, 2023 | 1.92 Mn |